Foxo transcription factors regulate cell cycle progression, cell survival and DNA-repair pathways. Here we demonstrate that deficiency in Foxo3 resulted in greater expansion of T cell populations after viral infection. This exaggerated expansion was not T cell intrinsic. Instead, it was caused by the enhanced capacity of Foxo3-deficient dendritic cells to sustain T cell viability by producing more interleukin 6. Stimulation of dendritic cells mediated by the coinhibitory molecule CTLA-4 induced nuclear localization of Foxo3, which in turn inhibited the production of interleukin 6 and tumor necrosis factor. Thus, Foxo3 acts to constrain the production of key inflammatory cytokines by dendritic cells and to control T cell survival.
Foxo transcription factors guide the cellular response to growth factors, nutrients and stress. This information is 'encoded' as post-translational modifications, referred to as the 'Foxo code' , that govern Foxo intracellular localization, cofactor associations and transcriptional activity. The resulting program of gene expression regulates cell cycle arrest, repair, apoptosis and autophagy and many other aspects of cellular homeostasis 1 . In mammals, four Foxo members have been identified. Foxo1 (FKH1 and FKHR) 2 , Foxo3 (FKHRL1; A000945) 3 , and Foxo4 (AFX) 4 are widely expressed and similarly regulated, whereas expression of Foxo6 (ref. 5 ) is confined to specific structures of the brain and is subject to distinct regulatory mechanisms.
Insulin, insulin-like growth factor and other growth factors induce activation of phosphatidylinositol-3-OH kinase and the kinase Akt, which phosphorylate three Foxo amino acids 6 . These modifications result in the association of the Foxo protein with the adaptor protein 14-3-3 and the nuclear exclusion and eventual degradation of Foxo3 (refs. 7-9) . This process can be actively opposed by stress-induced signals that activate the Jnk mitogen-activated protein kinase, which result in Foxo3 nuclear localization 10 . Foxo factor target specificity can be further refined by the SIRT1 deacetylase 11, 12 .
Given their involvement in coordinating cellular growth, proliferation and survival, we predicted that Foxo factors would be central to the highly dynamic, infection-mediated expansion and contraction of antigen-specific T cell populations. Indeed, Foxo activity is regulated by signaling by the T cell antigen receptor (TCR) and CD28, as well as by cytokines such as interleukin 2 (IL-2) 13 , IL-3 (ref. 14) and 16) . These stimuli result in the phosphorylation of Foxo by Akt, the kinase Sgk or inhibitor of transcription factor NF-kB (IkB) kinase, and in Foxo3 nuclear exclusion 17 . Withdrawal of growth factor causes dephosphorylation of nuclear Foxo3, binding of Foxo3 to the promoters of the genes encoding the proapoptotic molecules Bim and Puma, induction of transcription of those genes, and T cell apoptosis 18 . In contrast, enforced expression of a constitutively nuclear form of Foxo3 in T cell lines causes cell cycle arrest 13 . Furthermore, Foxo3 is involved in the persistence of CD4 + central memory T cells in mice and humans 19 .
Published studies have shown spontaneous T cell activation, lymphoproliferative disease and organ infiltration in 'Foxo3 Trap ' mice, which have a mutated Foxo3 allele generated by gene-trap technology 20 . Such studies indicate an important function for Foxo3 in immune regulation, although the underlying molecular mechanisms are not understood. In addition, Foxo3 regulates superoxide dismutase in dendritic cells (DCs); this signaling pathway may affect the suppressive or stimulating characteristics of plasmacytoid DCs 21, 22 .
In this study, we sought to determine whether Foxo3 is involved in the quiescence of cells of the immune system and the dynamics of T cell population expansion and contraction. We found that in response to LCMV infection, Foxo3 deficiency caused superabundant expansion of antigen-specific T cell populations. However, contrary to our expectations, this phenotype was not intrinsic to T cells but instead arose from altered stimulatory properties of Foxo3-deficient DCs. Foxo3 deficiency resulted in a DC-specific higher production of IL-6. Nuclear localization of Foxo3 induced by signals initiated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; A000706) suppressed Toll-like receptor-induced production of IL-6. Our results collectively emphasize the importance of Foxo3 in restraining the production of inflammatory cytokines by DCs and T cell viability.
RESULTS

No spontaneous activation of Foxo3-deficient T cells
To examine the function of Foxo3 in the immune system, we used two independently derived Foxo3-null strains distinct from the Foxo3 Trap mutant 20 . One strain, called 'Foxo3 Kca ' here, was backcrossed to the C57BL/6 strain, whereas mice of the other strain, called 'Foxo3 -/-' here, were maintained as congenic FVB mice. Although we detected strainspecific differences, deletion of Foxo3 had no effect on the proportion of T cells or B cells in the spleens and lymph nodes of 6-to 10-weekold mice ( Table 1) . However, we noted a greater proportion of Gr-1 hi CD11b hi cells, which include granulocytes and macrophages, in the spleens of both Foxo3-deficient strains. We detected neither lymphocytic organ infiltration nor lymphadenopathy 23 (data not shown) in 6-to 10-week-old Foxo3-deficient mice. However 3-to 6-month-old Foxo3-deficient mice had enlargement of the spleen and more erythrocyte progenitors (Ter119 + ; data not shown). That observation probably relates to the shorter erythrocyte lifespan and lower rate of erythrocyte maturation in Foxo3-deficient mice reported before 24 . Next we measured the expression of CD69, CD44 and CD62L (L-selectin) on T cells from Foxo3-deficient mice and their wild-type littermates. Although we again detected differences between the C57BL/6 and FVB strains, inactivation of Foxo3 had no effect on the proportion of activated (CD69 hi ) or memory-effector (CD44 hi CD62L lo ) T cells ( Fig. 1a) .
Published studies have shown constitutive activation of the NF-kB pathway in Foxo3 Trap mice, as reflected by the absence of IkB 20 . However, T cells purified from Foxo3 Kca and Foxo3 -/mice showed no change in the expression of IkBa, IkBb or IkBe protein relative to that of wild-type T cells ( Supplementary Fig. 1 online) . To measure the effect of Foxo3 deficiency on T cell proliferation, we labeled purified lymph node T cells with the cytosolic dye CFSE and then cultured the cells with plate-bound antibody to CD3 (anti-CD3) with or without anti-CD28. Neither the number of cell divisions nor the accumulation of cells in each division was altered by Foxo3 deficiency (Fig. 1b) . Also, freshly explanted Foxo3 Kca and wild-type CD4 + and CD8 + T cells produced similar amounts of cytokines ( Fig. 1c ). As FasL (CD95L), the ligand for the cell surface receptor Fas, is a known target of Foxo3, we also analyzed FasL expression on unstimulated and antibody-stimulated T cells from wild-type and Foxo3 Kca mice; however we found no differences related to Foxo3 status (data not shown). These results suggest that loss of Foxo3 alone is not sufficient to elicit manifestations of T cell activation and spontaneous autoimmunity.
Foxo3 Kca mice show enhanced T cell accumulation As Foxo3 is involved in cell cycle progression and apoptosis 25 , we sought to investigate its function in the dynamics of T cell population expansion and contraction in response to viral infection. Historically, the C57BL/6 strain has been used to study the progression of viral responses, and as the two mutant strains homozygous for Foxo3 deficiency had identical profiles here and in published results 23, 26 , our further efforts at characterization focused on the C57BL/6 Foxo3 Kca mice. We infected Foxo3 Kca mice and their wild-type littermates with lymphocytic choriomeningitis virus (LCMV) and assessed LCMVresponsive T cell populations at various times after infection. Whereas the Foxo3 genotype had no effect on the kinetics of T cell population expansion, Foxo3 Kca mice developed a threefold greater accumulation of LCMV-specific T cells than did their wild-type littermates (Fig. 2 ). Measurement of virus in the liver at day 8 after infection showed complete viral clearance in both strains (data not shown).
The lack of an effect of Foxo3 deficiency on T cells stimulated in culture prompted us to test whether the enhanced T cell accumulation during an LCMV response was T cell intrinsic. We transferred T cells from LCMV-specific TCR-transgenic P14 Foxo3 Kca or P14 wild-type mice into wild-type C57BL/6 mice and measured the accumulation of P14 T cells after infection of the recipient mice with LCMV. We detected no significant difference in the accumulation of Foxo3 Kca and wild-type P14 T cells ( Fig. 2b) . To further examine this issue, we transferred wild-type P14 T cells into either wild-type or Foxo3 Kca mice and infected recipients with LCMV. P14 T cells transferred into Foxo3 Kca mice accumulated in greater numbers than did P14 T cells transferred into wild-type hosts (Fig. 2b) . We reproduced that result with the transfer of ovalbumin (OVA)-specific OT-I T cells into wildtype and Foxo3 Kca hosts that we subsequently infected with OVAexpressing vesicular stomatitis virus ( Supplementary Fig. 2 online) .
To further investigate the cellular cause of the enhanced T cell population expansion, we reconstituted irradiated wild-type mice with bone marrow from wild-type or Foxo3 Kca mice. After 8 weeks, we infected the recipient mice with LCMV and analyzed expansion of the LCMV-specific T cell population. Excessive T cell accumulation was apparent in recipients of Foxo3 Kca bone marrow ( Fig. 2c) , which indicated involvement of a bone marrow-derived cell type in this phenotype. Thus, a non-T cell bone marrow-derived cell type was responsible for the enhanced T cell proliferation and/or survival in Foxo3-deficient mice.
Stimulatory capacity of DCs from Foxo3 Kca mice
The efficiency of antigen presentation can affect the magnitude of a T cell response to viral infection 27 . Therefore, we assessed whether Foxo3 regulates the number, phenotype and/or function of antigen-presenting DCs. Naive Foxo3 Kca mice had significantly more DCs than did their wild-type littermates (Fig. 3a) , and there was a slightly greater proportion of DCs with high expression of the costimulatory molecules B7-1 (CD80) and B7-2 (CD86). We found no difference in the expression of major histocompatibility complex (MHC) class I, MHC class II or CD40 on DCs from these mice ( Fig. 3b) , which suggested that a small number of Foxo3-deficient DCs had a more mature phenotype.
Analysis of various DC subsets showed that Foxo3-deficient mice had more CD11c + CD11b + CD8 -, CD11c + CD11b -CD8 + and CD11c + B220 + DCs (Fig. 3c) . All subsets showed a moderate shift toward high expression of B7-1 and B7-2 ( Fig. 3d ), although the biological importance of this shift is unclear. To further characterize the activation status of DCs from naive mice, we cultured splenic DCs overnight and then measured secreted cytokines. Foxo3 Kca DCs produced more IL-6, tumor necrosis factor (TNF) and chemokine CCL2 (MCP-1) than did wild-type DCs (Fig. 3e ). Interferon-g (IFN-g), IL-10 and IL-12 were undetectable (data not shown).
To determine whether DCs from Foxo3 Kca mice had enhanced antigen presentation, we infected mice with LCMV and analyzed DCs 3 d after infection, when virus is still present and T cell populations are expanding exponentially 28 . Compared with wildtype DCs, Foxo3 Kca DCs had slightly higher expression of B7-1, B7-2 and MHC class II ( Fig. 4a ) and more effectively stimulated the accumulation of P14 T cells, as measured by CFSE dilution and staining with annexin V and 7-amino-actinomycin D (7-AAD; Fig. 4b ). This enhanced stimulatory capacity was not due to a difference in antigen processing, as differences between cultures with Foxo3 Kca and wild-type DCs remained even after DCs were pulsed with LCMV glycoprotein 33 (gp33) peptide ( Fig. 4b) .
To rule out the possibility that Foxo3-deficient DCs from LCMVinfected mice can cause proliferation of bystander T cells independently of the presence of antigen, we also cultured DCs from LCMV-infected mice with OT-I T cells with or without OVA peptide (amino acids 257-264; OVA (257-264)). In the absence of OVA (257-264), there was no detectable division of OT-I T cells ( Fig. 4b) , which ruled out the possibility of bystander effects. Finally, we measured the capacity of DCs from uninfected mice to stimulate P14 T cells in the presence of gp33 peptide. We noted slightly greater accumulation and viability of T cells from cultures containing Foxo3 Kca DCs than from those containing wild-type DCs (Fig. 4c) .
To determine if the enhanced function of Foxo3-deficient DCs was cell autonomous, we generated DCs in vitro. For this, we cultured bone marrow cells for 8 d with granulocyte-macrophage colonystimulating factor. The number and proportion of the resulting CD11c + cells (called 'BMDCs' here) were unaffected by Foxo3 status, and none of the BMDCs had higher expression of B7-1, B7-2, CD40, MHC class I or MHC class II ( Supplementary Fig. 3a online). Consistent with published reports of cells stimulated with granulocyte-macrophage colony-stimulating factor, wild-type BMDCs had a uniformly cytoplasmic Foxo3 localization 29 ( Supplementary Fig. 3b ). Next we used BMDCs to stimulate OT-II and P14 T cells at various ratios of T cells to DCs. Foxo3 Kca BMDCs induced accumulation of OT-II and P14 T cells more effectively than did wild-type BMDCs (Fig. 5a) . Moreover, the Foxo3-deficient BMDCs also more effectively sustained T cell viability, regardless of cell division (Fig. 5b,c) . To determine whether the differences in viability correlated with changes in Bcl-2 family members, we analyzed expression of the prosurvival factors Bcl-2 and Bcl-x L . Total and naive CD44 lo T cells had higher expression of both when stimulated with Foxo3-deficient BMDCs (Fig. 5d) .
To assess the capacity of BMDCs to enhance T cell survival in vivo, we transferred CFSE-labeled OT-II T cells into naive CD45.1 congenic hosts. Then, 1 d later, we transferred wild-type or Foxo3-deficient BMDCs, with or without preloaded OVA peptide (amino acids 323-339; OVA(323-339), into the footpads of these mice. After 2 additional days, Foxo3 Kca BMDCs induced a greater accumulation of OT-II T cells in the draining lymph nodes but a similar number of OT-II T cell divisions, compared with wild-type DCs (Fig. 5e) . Notably, Foxo3 Kca DCs facilitated greater OT-II T cell survival, even in the absence of OVA(323-339). These data collectively establish that Foxo3-deficient DCs produce greater antigen-induced T cell population expansion by enhancing survival.
Enhanced IL-6 secretion by Foxo3-deficient DCs
To determine if the enhanced T cell survival induced by Foxo3deficient DCs was due to altered cytokine secretion, we infected wild-type and Foxo3 Kca mice with LCMV and measured cytokine concentrations in blood plasma at various times after infection. The concentrations of IL-12, IL-17, CCL2 (MCP-1), IL-1b, IL-5, IL-10 were similar in wild-type and Foxo3 Kca mice ( Supplementary Fig. 4a online), but the concentrations of IL-6 and TNF were higher in Foxo3deficient mice ( Fig. 6a and Supplementary Fig. 4a ). To determine if DCs were the source of this abundant IL-6 and TNF, we collected splenic DCs from mice on day 3 after infection and cultured the cells for 24 h. Supernatants of Foxo3 Kca DC cultures had significantly higher concentrations of IL-6, TNF, CCL2 (MCP-1) and IFN-g ( Fig. 6b and Supplementary Fig. 4b ), whereas we detected no difference in the concentration of IL-10 or IL-12. We also found higher expression of IL-6 mRNA in Foxo3 Kca DCs (Fig. 6b) .
To determine whether cells other than DCs could be responsible for the greater IL-6 production, we collected T cells, B cells and macrophages from mice 3 d after LCMV infection and cultured the cells for 24 h. Neither T cells nor B cells had detectable production of IL-6 (data not shown). Macrophages did produce IL-6, although there was no difference related to Foxo3 status (data not shown). However, given the finding of more macrophages in Foxo3-deficient mice, these cells may have contributed to the excess IL-6 production in vivo.
We next determined whether BMDCs also produced excess IL-6 in the absence of Foxo3. We detected significantly more IL-6 in cultures containing OT-II CD4 + T cells or OT-I CD8 + T cells and Foxo3 Kca BMDCs than in those containing T cells and wild-type DCs (Fig. 6c) . showed that Foxo3 Kca BMDCs had twofold more IL-6 mRNA than did wild-type BMDCs; IL-6 mRNA was at least tenfold greater in BMDCs than in CD4 + T cells, and IL-6 mRNA was undetectable in CD8 + T cells (Fig. 6d) .
In combination with transforming growth factor-b, IL-6 induces the differentiation of IL-17-producing T cells 30 . Given the results presented above, we analyzed the balance between IL-17-producing T cells and Foxp3 + regulatory T cells in Foxo3-deficient mice.
The proportion of Foxp3 + and IL-17 + CD4 + T cells in naive LCMV-infected Foxo3 Kca mice was similar to that of their wild-type littermates ( Supplementary Fig. 5 online) . We did not detect IL-17-producing cells in the CD8 + lineage (data not shown).
To evaluate whether the excess IL-6 produced by Foxo3-deficient DCs was required for their ability to induce enhanced T cell survival, we cultured OT-II and P14 T cells with BMDCs in the presence of an IL-6-specific blocking antibody or an immunoglobulin G1 (IgG1) isotype-matched control antibody. IL-6 blockade diminished the expansion of T cell populations cultured with Foxo3 Kca BMDCs to an amount resembling that of T cells cultured with wild-type DCs (Fig. 6e) that this reversion was due to lower T cell survival (Fig. 6f) . In addition, we determined whether exogenous IL-6 was sufficient to enhance the survival of T cells cultured with wild-type BMDCs. Indeed, we noted a direct correlation between the amount of IL-6 added and the proportion of live T cells in each culture 31 (Fig. 6g) .
To directly ascertain if IL-6 was responsible for the greater expansion of T cell populations in response to LCMV, we treated mice on days -1 and +4 (relative to LCMV infection at day 0) with 100 mg of blocking antibody to IL-6 receptor a-chain. Blockade of this receptor resulted in LCMV-specific T cell responses of substantially smaller magnitude in Foxo3-deficient mice but did not affect the number of LCMV-specific T cells in wild-type mice (Fig. 6h) . These experiments collectively suggest that wild-type DCs are restrained from abundant IL-6 production by Foxo3 and thus that the factors that affect the localization and transcriptional activity of Foxo3 will influence the magnitude of a T cell-mediated immune response.
Foxo3 acts 'downstream' of CTLA-4-induced signals
Stimulation of B7 receptors by CTLA-4 promotes nuclear localization of Foxo3 and activation of DCs 32 . As cell surface CTLA-4 expression is induced on activated T cells, we analyzed whether signaling through the B7 receptor inhibits IL-6 production in a Foxo3-dependent way. We stimulated splenic DCs with loxoribine, a Toll-like receptor 7 agonist, in the presence of varying amounts of a fusion of CTLA-4 and immunoglobulin (CTLA-4-Ig). The production of IL-6 and TNF stimulated by loxoribine was strongly inhibited by CTLA-4-Ig in wild-type DCs but not in Foxo3-deficient DCs (Fig. 7a) . Although treatment with CTLA-4-Ig resulted in a slightly greater proportion of dead cells, its toxic effects were equivalent in wild-type and Foxo3 Kca splenic DCs showed the same toxicity (Fig. 7a) .
To confirm the involvement of Foxo3 in the inhibition of cytokine production induced by CTLA-4-Ig, we analyzed the intracellular localization of Foxo3 after stimulation with loxoribine or CTLA-4-Ig. Foxo3 remained in the cytosol of unstimulated and loxoribine-treated BMDCs; however, CTLA-4-Ig stimulation strongly promoted the nuclear accumulation of Foxo3 (ref. 32 ; Fig. 7b ). Notably, signaling through B7 was dominant over Toll-like receptor 7 signals, as DCs treated with both loxoribine and CTLA-4-Ig showed Foxo3 nuclear localization. These experiments collectively show that CTLA-4-Ig treatment profoundly suppressed Toll-like receptor-induced production of IL-6 and TNF in wild-type DCs by promoting the nuclear accumulation of Foxo3.
If CTLA-4 signals DCs through B7-1 and B7-2, then blocking CTLA-4 should allow wild-type DCs, like Foxo3-deficient DCs, to enhance T cell survival. To investigate this issue, we cultured TCR-transgenic T cells in the presence of wild-type or Foxo3 Kca DCs and specific peptides with or without the addition of blocking antibody to CTLA-4. As expected, cultures with Foxo3 Kca BMDCs included more viable T cells than did cultures with wild-type BMDCs (Fig. 7c) . However, the addition of anti-CTLA-4 essentially eliminated the difference in T cell accumulation and viability in these cultures. The results of these experiments are consistent with the idea that CTLA-4 is involved in promoting the nuclear localization of Foxo3 and the resulting inhibition of inflammatory cytokines produced by DCs. Published experiments have shown that antibody specific for CTLA-4 can enhance an immune response in vivo 33, 34 , although, to our knowledge, this has not been demonstrated before in an immune response to LCMV. Nonetheless, we sought to determine whether we could detect Foxo3-dependent enhanced T cell population expansion. We inoculated mice with 100 mg of a CTLA-4-specific antibody and, 4 h later, infected the mice with LCMV. We further inoculated mice with a CTLA-4-specific antibody every other day and assessed the results on day 8. We did not find enhancement of T cell accumulation in either wild-type or Foxo3-deficient mice (Supplementary Fig. 6 online) .
DISCUSSION
In this report, we have established an essential function for Foxo3 in modulating the magnitude of antigen-specific T cell immune responses. Foxo3-deficient mice showed enhanced T cell proliferation in response to viral infection, an enhancement that was not T cell intrinsic but instead depended on the augmented capacity of DCs to sustain T cell viability. Despite the many potential targets of Foxo3, including regulators of cell cycle, apoptosis and reactive oxygen detoxification, Foxo3 loss-of-function mutation alone had no effect on the steady-state homeostasis, survival or proliferation of T cells. That finding is consistent with studies showing that Foxo1 is essential for normal T cell homeostasis and self tolerance 16 (data not shown). Instead, we found a critical DC-intrinsic function for Foxo3 in the control of T cell responses. Foxo3 acted 'downstream' of CTLA-4-induced signals to constrain IL-6 production by DCs. The natural conditions that would override the CTLA-4-mediated nuclear localization of Foxo3 are not known; however, a new immunostimulatory cancer treatment regimen that involves blocking CTLA-4 may act in part by this mechanism 35 .
Our results differ substantially from a published characterization of Foxo3 Trap mice 20 . Foxo3 Trap mutant mice were derived from an independent insertional mutant embryonic stem line obtained from BayGenomics and were backcrossed to the 129 strain for three generations. Foxo3 Trap mice show spontaneous T cell activation, lymphoproliferation and organ infiltration associated with constitutive activation of NF-kB. In contrast, we found none of those characteristics in Foxo3 -/or Foxo3 Kca mice. T cells isolated from these two strains of mice seemed to be indistinguishable from wildtype T cells in terms of NF-kB activation, expression of activation markers and response to mitogenic stimulation. Our results are consistent with published analyses of Foxo3 Kca and Foxo3 -/mice in that extensive histological analysis has not shown lymphocytic infiltration of organs 23, 26 .
Differences in autoimmunity are not uncommon in mixed C57BL/6 and 129 mouse strains. The 129 mice have autoimmunitysusceptibility loci, one of which (Sle16) induces humoral autoimmunity in congenic C57BL/6 mice. Several studies have noted modifier genes in 129 strains that confer enhanced autoimmune disease to 129 Â C57BL/6 mice [36] [37] [38] . Foxo Trap mice are apparently inbred 129 mice without a contribution from the C57BL/6 strain, but perhaps a 129 susceptibility locus that modifies the Foxo3 deficiency is present.
IL-6 is a pleiotropic cytokine that regulates many aspects of the immune system, including antibody production, hematopoiesis, inflammation and, most relevant to our study, T cell survival 39 . IL-6 'rescues' resting T cells from apoptosis by inhibiting the downregulation of Bcl-2 in a dose-dependent way 40 , and IL-6 increases the survival of antigen-stimulated T cells 31 . Consistent with that observation, we noted higher expression of Bcl-2 and Bcl-x L in T cells from LCMVinfected Foxo3 Kca mice than in those from wild-type mice. In addition, the division rate of T cells stimulated with Foxo3 Kca DCs was not different from that of T cells stimulated with wild-type DCs; instead, the effect was manifested as improved T cell survival. Moreover, Foxo3 Kca DCs sustained T cell viability both in vitro and in vivo even in the absence of specific peptide, which suggests that the enhanced T cell survival induced by IL-6 is not restricted to TCR-engaged T cells. Notably, IL-6-specific blocking antibody did not affect the viability of wild-type T cells in vitro, nor did it result in lower T cell accumulation in vivo. That observation indicates that in the conditions tested, the amount of IL-6 produced by wild-type DCs was not sufficient to affect T cell viability. It would be useful to determine whether immune responses to other agents are sensitive to IL-6 concentration and, in those infections, whether CTLA-4, regulatory T cells and Foxo3 affect the magnitude and dynamics of the T cell response. CTLA-4 acts as a counterbalance to costimulation of CD28 by antagonizing TCR signals in activated T cells and by promoting tolerance 41 . CTLA-4 is also expressed on regulatory T cells and is essential for their effectiveness 42 . CTLA-4 can also modify function of cells of the immune system by triggering 'reverse signaling' through B7 receptors; these signals promote the DC production of stimulatory and/or suppressive mediators 21 . Reverse signals through B7 also activate the immunosuppressive pathway of tryptophan catabolism in plasmacytoid DCs involving indoleamine 2,3-dioxygenase (IDO) 43 . Foxo3 is involved in the IDO pathway in plasmacytoid DCs, as CTLA-4-Ig leads to nuclear accumulation of Foxo3 and expression of superoxide dismutase 2 (ref. 32 ). As IDO induces T cell death through the generation of kinurenin and tryptophan privation 43 , we speculated that a potential IDO defect in Foxo3 Kca DCs could explain the improved T cell survival; however, addition of the IDO inhibitor 1-MT did not enhance T cell survival in cultures containing wild-type or Foxo3 Kca BMDCs (data not shown). Moreover, IDO is expressed mainly by plasmacytoid and CD8a + DC subsets 22 , and low or no IDO protein is detected in resting DCs derived from bone marrow 44 . Presumably CTLA-4 expressed on regulatory T cells constitutes the main B7-stimulatory ligand, but the possibility that activated T cells or other cells contribute to B7 ligation in vivo has not been investigated. In addition, the relative contribution of each CTLA-4-mediated suppressive mechanism to the regulation of immune responses to various infectious agents is not well understood.
Our experiments collectively indicate that nucleus-localized Foxo3 functions in DCs to inhibit the production of inflammatory cytokines that would otherwise be activated in response to infection. We deduce that the IL-6-induced T cell survival in Foxo3 Kca mice resulted from an inability of Foxo3-deficient DCs to shut down cytokine production in response to CTLA-4 signals. Conditions that alter Foxo3 activity, such as stress, growth factors or nutrients, would be expected to substantially influence the activity of DCs and perhaps macrophages, and such conditions might be expected to alter the outcome of responses to infectious agents.
METHODS
Mice. C57BL/6, C57BL/6-CD45.1, P14, OT-I and OT-II mice were maintained in specific pathogen-free conditions at the University of California, San Diego. C57BL/6 mice lacking Foxo3 were generated from embryonic stem cell clones from the OmniBank embryonic stem cell library of randomly targeted cell lines (Lexicon Genetics) 23 . These mice (Foxo3 Gt(VICTR20)1Kca ; called 'Foxo3 Kca ' here) were backcrossed to the C57BL/6J strain for 12 generations and were then intercrossed to generate congenic C57BL/6 Foxo3 Kca mice. 'Foxo L/L ' mice, with conditional targeting of Foxo3, were produced in FVB embryonic stem cells, and the loxP-flanked allele was deleted by breeding with male EIIa-Cre-transgenic mice 26 . Offspring with complete excision were bred to exclude EIIa-Cre; these mice are called 'Foxo3 -/-' here 26 . TCR-transgenic mice with a Foxo3-null genotype were produced by breeding of C57BL/6 Foxo3 Kca mice with either P14 or OT-II mice. All procedures were approved by the Institutional Animal Care and Use Committee of the University of California, San Diego.
Virus infection and analysis. Foxo3 Kca mice and their wild-type littermates 6-12 weeks of age were infected by intraperitoneal injection of 2 Â 10 5 plaque-forming units of LCMV, Armstrong strain, in 0.2 ml PBS. Alternatively, mice were infected with 1 Â 10 5 plaque-forming units of vesicular stomatitis virus 45 expressing OVA (provided by L. Lefrançois). At various times, spleens were collected from LCMV-infected mice and uninfected control mice and splenocytes were stimulated with gp33 peptide, an MHC class I-restricted LCMV epitope (gp33-41), or gp61 peptide, an MHC class II-restricted LCMV epitope (gp61-80; Genemed Synthesis) and brefeldin A (1 mg/ml; Golgistop; BD PharMingen). After 5 h of stimulation, cells were stained for intracellular IFN-g (XMG1.2; eBioscience). For transfer experiments, CD45.2 congenic wild-type P14 or Foxo3 Kca P14 T cells (2 Â 10 4 ) were injected intravenously into CD45.1 wild-type hosts, which were infected with LCMV 24 h later. Conversely, CD45.1 congenic wild-type P14 T cells were transferred into congenic CD45.2 wild-type littermate or Foxo3 Kca mice. P14 T cells in the spleen were counted at day 8 after LCMV infection. Infection with vesicular stomatitis virus was done in an identical way except that T cells from CD45.2 OT-I mice were transferred. For bone marrow-chimera experiments, congenic CD45.1 recipient mice were lethally irradiated (1,200 rads) and were injected intravenously with 2 Â 10 6 bone marrow cells from Foxo3 Kca or wild-type littermate donor mice (both CD45.2). After 2 months, the reconstitution of peripheral blood lymphocytes was over 90%. These radiation chimeras were then infected with LCMV and the magnitude of the LCMV response was assessed at day 8 after infection. For antibody blockade of IL-6 receptor a-chain, wild-type or Foxo3-deficient mice were inoculated intraperitoneally with 100 mg of antibody to IL-6 receptor a-chain (purified antibody to mouse and rat CD126; D7715A7; BioLegend) on day -1 and day +4 and were infected with LCMV, Armstrong strain, on day 0.
Cell isolation and purification. Bone marrow cells were isolated by flushing of the femur and tibia with RPMI medium (containing 10% (vol/vol) FBS, 2 mM L-glutamine, 100 U/ml of penicillin, 100 mg/ml of streptomycin and 50 mM b-mercaptoethanol). Spleens were removed and were incubated for 20 min at 37 1C with collagenase D (1 mg/ml; Roche), and splenocytes were collected by homogenization through a 100-mm tissue strainer. Cells were resuspended in Tris-ammonium chloride buffer for lysis of red blood cells. For purification of splenic DCs, cells were first incubated for 15 min with supernatants of 2.4G2 hybridoma cultures (anti-mouse FcgRII-III), then were incubated for 20 min with anti-mouse 'pan-DC' microbeads (Miltenyi Biotec), followed by positive selection. The positive fraction was typically over 95% CD11c + . For T cell purification, splenocytes from P14 or OT-II mice were incubated with a mixture of biotinylated anti-B220 (RA3-6B2), anti-CD19, anti-Gr-1 (RB6-8C5), anti-MHC class II, anti-DX5 and anti-CD11b (M1/70; all from eBioscience) and were negatively selected to over 95% purity with strepavidincoupled microbeads (Miltenyi Biotec).
BMDC cultures. Bone marrow cells were isolated and were cultured at a density of 2 Â 10 6 cells/ml in RPMI medium containing recombinant mouse granulocyte-macrophage colony-stimulating factor (20 ng/ml; Peprotech). On days 2, 4 and 6, half the culture was removed and centrifuged and the cell pellet was resuspended in 10 ml fresh media containing recombinant mouse granulocyte-macrophage colony-stimulating factor (20 ng/ml). Cultures were collected on day 8 and CD11c + cells were selected with microbeads (Miltenyi Biotec). The final population was 98% CD11c + CD11b + B220 -DCs.
Flow cytometry. Cells were incubated for 15 min with anti-mouse FcgRII-III and then were stained with primary antibodies for 20 min on ice. The following mouse monoclonal antibodies were used (all from eBioscience): allophycocyanin-or phycoerythrin-conjugated anti-CD11c (N418); fluorescein isothiocyanate-or phycoerythrin-conjugated anti-B220 (RA3-6B2); phycoerythrin-indotricarbocyanine-or peridin chlorophyll protein-conjugated anti-CD11b (M1/70); allophycocyanin-conjugated anti-CD8a (53-6.7); fluorescein isothiocyanate-conjugated anti-MHC class I and anti-Gr-1 (RB6-8C5); peridin chlorophyll protein-conjugated anti-CD3; and phycoerythrinconjugated anti-CD86, anti-CD80, anti-MHC class II, anti-Ly6C, anti-CD19, anti-CD3 and anti-NK1.1.
T cell proliferation and death assays. For in vitro experiments, DCs were purified from wild-type or Foxo3 Kca mice on day 3 after LCMV infection. DCs were also purified from uninfected mice or were derived from the bone marrow of wild-type or Foxo3 Kca mice. These DCs were used to stimulated P14 CD8 + T cells, OT-II CD4 + T cells or OT-I CD8 + T cells (1 Â 10 5 cells per well) labeled with 1 mM CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes) in the presence of gp33 peptide (0.1 mg/ml) or OVA(323-339); (1 mg/ml). Proliferation was analyzed by flow cytometry by measurement of CFSE dilution, and T cell death was measured by staining with annexin V and 7-AAD. For in vivo transfer experiments, CFSE-labeled CD4 + T cells purified from OT-II mice were injected retro-orbitally into congenic CD45.1 C57BL/6 mice. Wild-type or Foxo3 Kca BMDCs were pulsed with OVA(323-339) and were injected intradermally after 24 h. Then, 3 d later, draining lymph nodes were collected, were stained with allophycocyanin-conjugated anti-CD4 (GK1.5) and phycoerythrin-conjugated anti-CD45.1 (A20; both from eBioscience) and were analyzed by flow cytometry.
In vitro stimulation of DCs and quantification of cytokine production. Sorted DCs (2 Â 10 5 ) were cultured in 96-well round-bottomed culture plates (Nunc) and were stimulated with medium alone or 0.03 mM loxoribine (InvivoGen) alone or in the presence of a recombinant mouse fusion protein consisting of the ectodomain of CTLA-4 linked to the Fc portion of IgG2a (CTLA-4-Ig) at a concentration of 20 or 40 mg/ml (R&D Systems). After culture for 18 h, supernatants were collected and cytokine concentrations were determined by immunoassay. Enzyme-linked immunosorbent assay kits were used for the detection of TNF or IL-6 (Ready-Set-Go; eBioscience) unless otherwise specified. Cytokines were also measured by cytokine bead array (BD Biosciences) or Luminex technology (Invitrogen).
